Who
Gregory L. Weaver
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Altimmune; Former EVP, CFO, & Director, Atossa Therapeutics; Chief Financial Officer, ATAI Life Sciences; Chief Financial Officer, Eloxx Pharmaceuticals; Director, Egalet; Chief Financial Officer, Fibrocell Science; CFO, Imunon; Chief Financial Officer, Poniard Pharmaceuticals.
In numbers
- Trades disclosed
- 118
- Buys
- 15
- Sells
- 3
- Bought
- $556K
- Sold
- $672K
- Companies
- 10
- Companies where not an officer
- 2
- First trade
- 13 Feb 2006
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code M | —14,475 at $0.00 | filing |
| 1 Oct 2026filed 5 Oct 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code F | $12K4,379 at $2.76 | filing |
| 1 Oct 2026filed 5 Oct 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,475 at $0.00 | filing |
| 31 Jul 2026filed 3 Aug 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code A | $4,2321,753 at $2.41 | filing |
| 31 Jul 2026filed 3 Aug 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Code A | $4,2251,753 at $2.41 | filing |
| 1 Apr 2026filed 1 Apr 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Bought | $31K10,000 at $3.15 | filing |
| 1 Apr 2026filed 1 Apr 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Bought | $32K10,000 at $3.15 | filing |
| 6 Mar 2026filed 9 Mar 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Bought | $18K5,000 at $3.54 | filing |
| 6 Mar 2026filed 9 Mar 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Bought | $18K5,000 at $3.54 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —259,000 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —111,000 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —259,000 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —111,000 at $0.00 | filing |
| 11 Nov 2025filed 12 Nov 2025 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,750 at $0.00 | filing |
| 11 Nov 2025filed 12 Nov 2025 | ALT AltimmuneBiotechnology | SEC FORM 4 Code M | —18,750 at $0.00 | filing |
| 11 Nov 2025filed 12 Nov 2025 | ALT AltimmuneBiotechnology | SEC FORM 4 Code F | $24K5,672 at $4.28 | filing |
| 1 Oct 2025filed 3 Oct 2025 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —166,800 at $0.00 | filing |
| 1 Oct 2025filed 3 Oct 2025 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —57,900 at $0.00 | filing |
| 13 Mar 2025filed 14 Mar 2025 | ALT AltimmuneBiotechnology | SEC FORM 4 Bought | $52K10,000 at $5.20 | filing |
| 11 Nov 2024filed 12 Nov 2024 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,000 at $0.00 | filing |
News
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026ALT · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name Gregory L. Weaver; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.